Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company committing to providing novel solutions for oncology, respiratory disease and other therapeutic areas by applying its proprietary AnticalinÂŽ technology to create differentiated drugs. In 2017, Pieris forged strategic alliances with Servier and AstraZeneca to accelerate its transformation into a fully-integrated, biologics R&D and commercial organization, focused on two immunology-related therapeutic areas: immuno-oncology and respiratory disease. The foundation of Pieris' partnerships and R&D efforts is a proprietary class of clinically-tested next generation therapeutics, Anticalin proteins.
Source
